LT2920168T - Heterociklinis gliutaminazės inhibitorius - Google Patents

Heterociklinis gliutaminazės inhibitorius

Info

Publication number
LT2920168T
LT2920168T LTEPPCT/US2013/070277T LT13070277T LT2920168T LT 2920168 T LT2920168 T LT 2920168T LT 13070277 T LT13070277 T LT 13070277T LT 2920168 T LT2920168 T LT 2920168T
Authority
LT
Lithuania
Prior art keywords
heterocyclic
glutaminase inhibitor
glutaminase
inhibitor
heterocyclic glutaminase
Prior art date
Application number
LTEPPCT/US2013/070277T
Other languages
English (en)
Lithuanian (lt)
Inventor
Jim Li
Lijing Chen
Bindu Goyal
Guy Laidig
Timothy STANTON
Eric Sjogren
Original Assignee
Calithera Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calithera Biosciences, Inc. filed Critical Calithera Biosciences, Inc.
Publication of LT2920168T publication Critical patent/LT2920168T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/121,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/1251,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEPPCT/US2013/070277T 2012-11-16 2013-11-15 Heterociklinis gliutaminazės inhibitorius LT2920168T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261727195P 2012-11-16 2012-11-16
US201361824434P 2013-05-17 2013-05-17
PCT/US2013/070277 WO2014078645A1 (en) 2012-11-16 2013-11-15 Heterocyclic glutaminase inhibitors

Publications (1)

Publication Number Publication Date
LT2920168T true LT2920168T (lt) 2021-10-25

Family

ID=50731715

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2013/070277T LT2920168T (lt) 2012-11-16 2013-11-15 Heterociklinis gliutaminazės inhibitorius

Country Status (25)

Country Link
US (2) US10793535B2 (OSRAM)
EP (2) EP3954686A1 (OSRAM)
JP (1) JP6275153B2 (OSRAM)
KR (1) KR102220175B1 (OSRAM)
CN (1) CN105051041B (OSRAM)
AU (1) AU2013344560B2 (OSRAM)
BR (1) BR112015010955A2 (OSRAM)
CA (1) CA2891667A1 (OSRAM)
CY (1) CY1125279T1 (OSRAM)
DK (1) DK2920168T3 (OSRAM)
EA (1) EA029707B1 (OSRAM)
ES (1) ES2899461T3 (OSRAM)
HR (1) HRP20211610T1 (OSRAM)
HU (1) HUE056078T2 (OSRAM)
IL (1) IL238787A0 (OSRAM)
LT (1) LT2920168T (OSRAM)
MX (1) MX381260B (OSRAM)
PL (1) PL2920168T3 (OSRAM)
PT (1) PT2920168T (OSRAM)
RS (1) RS62447B1 (OSRAM)
SG (1) SG11201503720SA (OSRAM)
SI (1) SI2920168T1 (OSRAM)
SM (1) SMT202100589T1 (OSRAM)
WO (1) WO2014078645A1 (OSRAM)
ZA (2) ZA201504294B (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
ES2899461T3 (es) 2012-11-16 2022-03-11 Calithera Biosciences Inc Inhibidores heterocíclicos de glutaminasa
CN105283182A (zh) * 2012-12-03 2016-01-27 卡利泰拉生物科技公司 用谷氨酰胺酶的杂环抑制剂治疗癌症
CN111892589A (zh) 2014-01-06 2020-11-06 理森制药股份公司 谷氨酰胺酶抑制剂
CR20160497A (es) * 2014-04-30 2016-12-20 Pfizer Derivados de diheterociclo enlazado a cicloalquilo
GB201409624D0 (en) 2014-05-30 2014-07-16 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
MX374924B (es) * 2014-06-13 2025-03-06 Calithera Biosciences Inc Terapia de combinacion con inhibidores de glutaminasa.
WO2016004413A2 (en) * 2014-07-03 2016-01-07 Board Of Regents, University Of Texas System Gls1 inhibitors for treating disease
SI3164394T1 (sl) 2014-07-03 2020-08-31 Board Of Regents, The University Of Texas System GLS1 inhibitorji za zdravljenje bolezni
DK3164195T3 (da) * 2014-07-03 2022-07-11 Univ Texas Glutaminaseinhibitorterapi
WO2016007647A1 (en) 2014-07-09 2016-01-14 The Johns Hopkins University Glutaminase inhibitor discovery and nanoparticle-enhanced delivery for cancer therapy
BR112017002403A2 (pt) * 2014-08-07 2017-12-05 Calithera Biosciences Inc formas de cristais de inibidores de glutaminase
US20160287564A1 (en) * 2015-03-30 2016-10-06 Calithera Biosciences, Inc. Methods of administering glutaminase inhibitors
CA2981762A1 (en) 2015-04-06 2016-10-13 Calithera Biosciences, Inc. Treatment of lung cancer with inhibitors of glutaminase
WO2017004359A1 (en) 2015-06-30 2017-01-05 Board Of Regents, University Of Texas System Gls1 inhibitors for treating disease
CN108601767A (zh) 2015-10-05 2018-09-28 卡利泰拉生物科技公司 用谷氨酰胺酶抑制剂和免疫肿瘤学药剂的组合疗法
US9938265B2 (en) * 2015-11-30 2018-04-10 Astrazeneca Ab 1,3,4-thiadiazole compounds and their use in treating cancer
TW201733587A (zh) * 2015-11-30 2017-10-01 阿斯特捷利康公司 1,3,4-噻二唑化合物及其在治療癌症中之用途
CN108602782B (zh) 2015-12-22 2022-06-17 德克萨斯大学系统董事会 N-甲基-1h-1,2,3-三唑-4-甲酰胺化合物的盐形式和多晶型物
JP2019524852A (ja) * 2016-08-25 2019-09-05 キャリセラ バイオサイエンシーズ, インコーポレイテッド グルタミナーゼ阻害剤を用いる併用療法
US10278968B2 (en) * 2016-08-25 2019-05-07 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
US20180055825A1 (en) * 2016-08-25 2018-03-01 Yu Liang Treatment of cancer with inhibitors of glutaminase
ES2903182T3 (es) 2017-06-13 2022-03-31 Medshine Discovery Inc Compuesto como inhibidor GLS1
CN111225903B (zh) 2017-10-18 2024-08-16 德州大学系统董事会 谷氨酰胺酶抑制剂疗法
CN110746416A (zh) * 2019-09-05 2020-02-04 中国药科大学 含有三氮唑结构的谷氨酰胺酶gls1抑制剂或其可药用的盐、其制备方法及用途
CN114805346A (zh) * 2021-07-08 2022-07-29 成都硕德药业有限公司 杂环类衍生物、其制备方法及用途

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1019519A (en) 1911-07-11 1912-03-05 Oscar Martin Polin Apparatus for making backing for teeth.
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
DE69839355T2 (de) 1997-07-29 2009-06-04 Alcon Laboratories, Inc., Fort Worth Ophthalmische Zusammensetzungen enthaltend Galaktomannanpolymere und Borat
US6310093B1 (en) 1997-08-29 2001-10-30 Elan Pharmaceuticals, Inc. Method of preventing neuronal death
WO1999038504A1 (en) 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (-)-bupropion
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US6451828B1 (en) 2000-08-10 2002-09-17 Elan Pharmaceuticals, Inc. Selective inhibition of glutaminase by bis-thiadiazoles
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
DK1654002T4 (da) 2003-08-07 2014-02-17 Allergan Inc Sammensætninger til fremføring af terapeutiske midler til øjnene
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
JP4885122B2 (ja) 2004-04-15 2012-02-29 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 癌、器官傷害、および筋肉リハビリテーション/運動過剰訓練についての診断の生物マーカーとしてのタンパク質分解マーカー
WO2011143160A2 (en) 2010-05-10 2011-11-17 The Johns Hopkins University Metabolic inhibitor against tumors having an idh mutation
US20110281234A1 (en) 2010-05-12 2011-11-17 Colton Crane System and methods for removing a loose tooth
US10064885B2 (en) 2010-07-09 2018-09-04 Massachusetts Institute Of Technology Metabolic gene, enzyme, and flux targets for cancer therapy
CA2742342A1 (en) 2011-02-12 2012-08-12 Baylor Research Institute Msh3 expression status determines the responsiveness of cancer cells to the chemotherapeutic treatment with parp inhibitors and platinum drugs
FI20115876A0 (fi) 2011-09-06 2011-09-06 Turun Yliopisto Yhdistelmähoito
ES2761866T3 (es) * 2011-11-21 2020-05-21 Calithera Biosciences Inc Inhibidores heterocíclicos de glutaminasa
US8604016B2 (en) 2011-11-21 2013-12-10 Calithera Biosciences Inc. Heterocyclic inhibitors of glutaminase
ES2899461T3 (es) 2012-11-16 2022-03-11 Calithera Biosciences Inc Inhibidores heterocíclicos de glutaminasa
SG11201504022RA (en) 2012-11-21 2015-06-29 Agios Pharmaceuticals Inc Glutamase inhibitors and method of use
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
CN105283182A (zh) 2012-12-03 2016-01-27 卡利泰拉生物科技公司 用谷氨酰胺酶的杂环抑制剂治疗癌症
WO2015061432A1 (en) 2013-10-25 2015-04-30 Calithera Biosciences, Inc. Treatment of viral infections with inhibitors of glutaminase
EP3116872A4 (en) 2014-03-14 2017-08-30 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
MX374924B (es) 2014-06-13 2025-03-06 Calithera Biosciences Inc Terapia de combinacion con inhibidores de glutaminasa.
BR112017002403A2 (pt) 2014-08-07 2017-12-05 Calithera Biosciences Inc formas de cristais de inibidores de glutaminase
US20160287564A1 (en) 2015-03-30 2016-10-06 Calithera Biosciences, Inc. Methods of administering glutaminase inhibitors
CA2981762A1 (en) 2015-04-06 2016-10-13 Calithera Biosciences, Inc. Treatment of lung cancer with inhibitors of glutaminase
CN108601767A (zh) 2015-10-05 2018-09-28 卡利泰拉生物科技公司 用谷氨酰胺酶抑制剂和免疫肿瘤学药剂的组合疗法
US10278968B2 (en) 2016-08-25 2019-05-07 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors
JP2020510032A (ja) 2017-03-10 2020-04-02 キャリセラ バイオサイエンシーズ, インコーポレイテッド グルタミナーゼ阻害剤との併用療法

Also Published As

Publication number Publication date
HK1215023A1 (zh) 2016-08-12
KR20150085053A (ko) 2015-07-22
MX381260B (es) 2025-03-12
JP2016505526A (ja) 2016-02-25
CN105051041A (zh) 2015-11-11
BR112015010955A2 (pt) 2017-07-11
EP2920168B1 (en) 2021-07-21
SMT202100589T1 (it) 2021-11-12
US20210292289A1 (en) 2021-09-23
IL238787A0 (en) 2015-06-30
US20140194421A1 (en) 2014-07-10
CN105051041B (zh) 2018-03-30
RS62447B1 (sr) 2021-11-30
AU2013344560B2 (en) 2017-09-14
EA201590941A1 (ru) 2016-02-29
EP3954686A1 (en) 2022-02-16
EP2920168A4 (en) 2016-04-20
CA2891667A1 (en) 2014-05-22
HUE056078T2 (hu) 2022-01-28
DK2920168T3 (da) 2021-10-18
ZA201504294B (en) 2018-12-19
WO2014078645A1 (en) 2014-05-22
CY1125279T1 (el) 2023-03-24
EA029707B1 (ru) 2018-05-31
JP6275153B2 (ja) 2018-02-07
SG11201503720SA (en) 2015-06-29
HRP20211610T1 (hr) 2022-02-04
US10793535B2 (en) 2020-10-06
MX2015005963A (es) 2015-09-16
PT2920168T (pt) 2021-10-18
PL2920168T3 (pl) 2022-01-03
KR102220175B1 (ko) 2021-02-24
ES2899461T3 (es) 2022-03-11
EP2920168A1 (en) 2015-09-23
SI2920168T1 (sl) 2022-01-31
ZA201606590B (en) 2019-04-24

Similar Documents

Publication Publication Date Title
CY2022027I1 (el) Παραγωγα βενζιμιδαζολο-προλινης
LT2920168T (lt) Heterociklinis gliutaminazės inhibitorius
EP2782570A4 (en) HETEROCYCLIC INHIBITORS OF GLUTAMINASE
LT2841428T (lt) Dnr-pk inhibitoriai
SMT201700052B (it) 2-(azaindol-2-il)benzimidazoli come inibitori di pad4
HRP20181527T1 (hr) Inhibitor ret
SMT201600114B (it) Inibitori di beta-secretasi
HUE036259T2 (hu) Inhibitor vegyületek
EP2928898A4 (en) BETA-Lactamase INHIBITORS
LT3057586T (lt) Bromodomeno inhibitoriai
EP2969007A4 (en) HISTONE DEMETHYLASE INHIBITORS
PT2934145T (pt) Inibidores de histona demetilase
AR095266A1 (es) Inhibidores de bromodominios tetraciclicos
HRP20182037T1 (hr) Inhibitori prmt5 i njihova uporaba
LT2895484T (lt) Gliukozilceramido sintazės inhibitoriai
LT3080100T (lt) Lizinui specifinės demetilazės-1 inhibitoriai
HUE037662T2 (hu) SYK inhibitorok
DK2804858T3 (da) Metalloenzym-inhibitorforbindelser
ME02985B (me) Prolekovi inhibitora amino-hinazolinske kinaze
SMT201600357B (it) Inibitori di iap
EP3020718A4 (en) NOVEL PDE4 INHIBITOR
EP2858975A4 (en) FBXO3 INHIBITORS
EP2847201A4 (en) 6-oxo-purin-phosphoribosyl INHIBITORS
EP2882430A4 (en) ANTIBACTERIAL INHIBITORS
FR2997080B1 (fr) Inhibiteurs de neprilysine